C&EN: Odyssey Therapeutics launches with $218 million

Ryan Cross

Odyssey Therapeutics isn’t Gary Glick’s first biotech start-up. Or his second. It’s his fifth. The serial entrepreneur has earned a reputation for launching one company after another to develop small-molecule drugs for cancer and immune diseases. Many of those firms, working on popular targets including STING and the NLRP3 inflammasome, were quickly snatched up by larger firms. But Odyssey could be his biggest venture yet.

Read more